Unlike other melatonin products, REMfresh’s patented technology releases melatonin continuously for up to 7 hours, mimicking the body’s natural release of melatonin.

This may help you fall asleep faster, stay asleep longer†, and experience better quality sleep.

REMfresh is not a prescription drug. It doesn’t contain narcotics, sedatives, antihistamines, or alcohol. REMfresh doesn’t cause morning drowsiness and isn’t associated with dependence or withdrawal symptoms.

REMfresh helps you wake up refreshed without a drug hangover effect.

 

Our pill works Smarter See the Ion-Powered Difference.

Works Long

The only Melatonin with 7-Hour action

7-plus-hour-icon

+ hours

REMfresh exceeded the targeted sleep maintenance threshold.1



Works Safely

No Pattern Of Side EffectsNo Concern on Safety Profile

works-safely-icon

+ Percent

In a study, 99.4 percent of patients indicated they were likely or very likely to continue taking REMfresh for their sleep issues.2

Works with Quality

Quality Ingredients, Pharmaceutical - Quality Manufacturing

doctor-icon

+ Physicians

Over 5,000 physicians are recommending REMfresh.3


Is REMfresh® right for you ?

Take our quiz to find your personalized sleep solution.

Start Now
REMfresh arrow Real World StudiesREMSU24REMAKTREMVALREMSS

 

The clinical and real-world data behind REMfresh® is unprecedented for any melatonin product offered in the United States. REMfresh’s 7-hour innovation is supported by three lanes of clinical proof. First is the breakthrough 7-hour Pharmacokinetic Data (REMAKT), second is the depth of real-world patient-reported data found in REMVAL and REMSS, and finally the REMSU24 study, one of the few large-scale adverse event reports on melatonin that has been peer reviewed, which points to REMfresh’s outstanding safety profile.4

The Mesa Wave™ Pattern

The Mesa Wave™ Pattern

REMfresh’s patented Ion-Powered Pump™ technology releases high-quality melatonin continuously throughout the night, mimicking the body’s natural release profile.†

In some other products, melatonin release peaks after the first few hours of sleep and decreases sharply thereafter.

REMfresh’s release pattern of melatonin throughout the night resembles a mesa – a flat-topped hill with steep sides. It’s estimated that one-third of adults have occasional difficulty falling or staying asleep. This may be because their body is no longer producing this Mesa Wave™ pattern of melatonin release.

REMfresh Pharmacokinetics mesa wave pattern

Find REMfresh® in a store near you!

Find Store

References

  1. REM Absorption Kinetics Trial (REMAKT) a pharmacokinetics trial of 5 mg REMfresh, not a sleep study. Results peer-reviewed and published in Primary Care Companion for CNS Disordersjournal, 2019.
  2. Brodner DC, Seiden DJ, Shah SM (2019). Observed Hypnotic Effects with a Continuous-Release Ion Powered Pump Melatonin Delivery System: Self-Reported Patient Outcomes Study Results Demonstrating Improvement in Sleep Duration and Quality. (Abstract 0399). Poster Presented at SLEEP 2019, San Antonio, Texas.
  3. Data on file.
  4. *Seiden, D.J., & Shah, S.M. A Randomized, Crossover, Pharmacokinetics Evaluation of a Novel Continuous Release and Absorption Melatonin Formulation. Primary Care Companion for CNS Disorders 2019.
Is REMfresh right for you ?

Find REMfresh® in a store near you!

Find Store

References

  1. REM Absorption Kinetics Trial (REMAKT) a pharmacokinetics trial of 5 mg REMfresh, not a sleep study. Results peer-reviewed and published in Primary Care Companion for CNS Disordersjournal, 2019.
  2. Brodner DC, Seiden DJ, Shah SM (2019). Observed Hypnotic Effects with a Continuous-Release Ion Powered Pump Melatonin Delivery System: Self-Reported Patient Outcomes Study Results Demonstrating Improvement in Sleep Duration and Quality. (Abstract 0399). Poster Presented at SLEEP 2019, San Antonio, Texas.
  3. Data on file.
  4. *Seiden, D.J., & Shah, S.M. A Randomized, Crossover, Pharmacokinetics Evaluation of a Novel Continuous Release and Absorption Melatonin Formulation. Primary Care Companion for CNS Disorders 2019.